


EORTC CLTF 2012

TARGETS FOR THERAPY IN
CUTANEOUS LYMPHOMAS

7.-9. September 2012
Vienna, Austria



PROGRAMME

Dear Colleagues and Friends,

It is a great honor and pleasure to welcome you in Vienna to the 2012 annual clinically oriented meeting of the EORTC Cutaneous Lymphoma Task Force.

Our goal is to highlight important new developments in the areas of clinical and basic sciences as well as pathogenesis, diagnosis, and therapy of cutaneous lymphomas.

A major focus of this meeting will be to discuss and identify TARGETS FOR THERAPY IN CUTANEOUS LYMPHOMAS.

For this purpose we welcome the active participation of all of you that will help us gain further insight into this highly promising, exciting and rapidly developing area of medicine and oncology.

As has become tradition the meeting includes oral and poster presentations of significance in the treatment and pathology of cutaneous lymphomas.

We wish you a fruitful and enjoyable meeting.

Robert Knobler, Franz Trautinger
Local organizers



EORTC CLTF 2012

TARGETS FOR THERAPY IN CUTANEOUS LYMPHOMAS

September 7-9, 2012

Vienna, Austria

LOCAL ORGANIZING CHAIRMEN:

Robert Knobler, M.D.

Assoc. Prof. of Dermatology
Lymphoma and Photopheresis Clinic
Department of Dermatology
Medical University of Vienna
Währinger Gürtel 18-20
1090 Vienna, Austria
Tel: +43 1 40 400 7807
Fax: +43 1 40 400 7808
email: robert.knobler@meduniwien.ac.at

Franz Trautinger, M.D.

University Professor
Department of Dermatology and
Venereology, Landeskrankenhaus St. Pölten
Karl Landsteiner Institute of Dermatological
Research
Propst-Führer-Strasse 4
3100 St. Pölten, Austria
Tel +43-2742-300-11909
Fax +43-2742-300-11919
email: franz.trautinger@stpoelten.lknoe.at

LOCAL SCIENTIFIC & ORGANIZING COMMITTEE

Wolfgang Bauer
Lorenzo Cerroni
Johanna Eder
Ulrich Jäger
Constanze Jonak

Leonhard Müllauer
Hubert Pehamberger
Markus Raderer
Matthias Schmuth
Julia Valencak

MEETING COORDINATOR & SPONSORSHIP & EXHIBITION SALES CONTACT

Ursula Partsch-Brokke Tagungsmanagement

A - 2560 Berndorf, PF 41
Tel/Fax: +43 (0)2672 88 99 6
email: office@tagungsmanagement.org

CONFERENCE VENUE

Austria Trend Parkhotel Schönbrunn
Hietzinger Hauptstr. 10-14, A - 1130 Vienna
Tel.: +43 (1) 87 804-0 | Fax: +43 (1) 87 804-3220
<http://www.austria-trend.at/Parkhotel-Schoenbrunn>
parkhotel.schoenbrunn@austria-trend.at



SCHEDULE

Friday, September 7 14:00 until 19:00
Saturday, September 8 08:30 until 18:30
Sunday, September 9 08:30 until 13:00

REGISTRATION www.eortc-cltf2012.eu

Friday, Sept. 7: 11.00 Registration opens at Welcome Desk, Parkhotel Schönbrunn

REGISTRATION CATEGORY	UNTIL JULY 31, 2012	AFTER AUGUST 1, 2012	ON-SITE
EORTC members	<input type="checkbox"/> 210	<input type="checkbox"/> 260	<input type="checkbox"/> 260
Non-members	<input type="checkbox"/> 400	<input type="checkbox"/> 450	<input type="checkbox"/> 450
Accompanying persons	<input type="checkbox"/> 100	<input type="checkbox"/> 100	<input type="checkbox"/> 100

Bank: Hypo NÖ Landesbank

Account name: Karl Landsteiner-Gesellschaft c/o Prim. Dr. Franz Trautinger

Account number: 3455037920

Bank code: 53000

IBAN: AT315300003455037920

BIC/SWIFT code: HYPNATWW

Payment in advance for the Congress must be received in order to confirm your registration. Once your payment has been accepted, a letter of confirmation will be sent to you via e-mail.

ABSTRACTS

A USB flash drive with an electronic abstract book in PDF-format will be provided to all registrants. The abstract book will also be available for free download from the congress webpage www.eortc-cltf2012.eu.

SOCIAL EVENTS

Sept. 7, 19:00 Welcome Reception at the Parkhotel Schönbrunn

Sept. 8, 20:00 Dinner at the Vienna City Hall

OFFICIAL LANGUAGE

The official language of the meeting is English.

No simultaneous translation will be provided.

For more information about hotel accomodation, flights to Vienna, airport transfers, sight-seeing tours, etc: <http://www.austropa-interconvention.at/book/?lang=en>

PROGRAMME

Friday, September 7, 2012

11.00 Registration opens at Welcome Desk
Parkhotel Schönbrunn

12.00-13.30 **EORTC closed business meeting**
Meeting room Sophie

14.00-15.45 **S01: Pathology and biology of cutaneous lymphomas I**

Chairs: M. Vermeer and P. Quaglino

S01-01. Report of the 2011 SH/EAHP workshop on cutaneous lymphomas and their mimics.
R. Willemze (Leiden) - 20 min

S01-02. Diagnosis of follicular B-cell lymphoma: new findings and their influence on therapeutic strategies.
C. Massone, L. Cerroni (Graz) - 20 min

S01-03. Histopathologic criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a EORTC Cutaneous Lymphoma Group study of 101 cases.
C.D. Klemke (Mannheim) - 20 min

S01-04. EORTC study on biomarkers for Sézary syndrome.
S.E. Boonk, W.H. Zoutman, C.P. Tensen et al. (Leiden) - 20 min

S01-05. MicroRNA profiling of primary cutaneous large B-cell lymphoma.
L. Koens, Y. Qin, W.Y. Leung, et al. (Leiden) - 20 min

15.45-16.00 **Coffee break**

16.00-17.45 **S02: Pathology and biology of cutaneous lymphomas II**

Chairs: P.L. Ortiz Romero and S. Whittaker

S02-01. A bio-informatic approach identifies a high resolution genomic fingerprint characteristic for mycosis fungoides.
M.S. van Kester, M. Borg, W.H. Zoutman, et al. (Leiden) - presented by C.P. Tensen - 17 min

- S02-02.** Regulation of cell survival in cutaneous T-cell lymphomas by microRNAs.
V. Manfé, E. Biskup, A. Guldhammer Skov, et al. (Copenhagen)
- 17 min
- S02-03.** Phosphatidylinositol-3 kinase (PI3K)/serine/threonine protein (AKT) pathway in mycosis fungoides.
E. Papadavid, P. Korkolopoulou, T. Papadaki, et al. (Athens)
- 17 min
- S02-04.** Role of transcription factors in the pathogenesis of cutaneous lymphoma.
C. Assaf (Krefeld) - 17 min
- S02-05.** Angiogenesis in cutaneous lymphomas.
M. Felcht (Mannheim) - 17 min

17.45-18.00 **Coffee break**

18.00-19.00 **Free communications I**

Chairs: R. Dummer and M. Marshalko

-
- FC-01.** Kimura disease: retrospective multicentric study of 25 french cases.
M. Battistella, D. Kottler, B. Crickx, et al. (Paris, Lyon, Nantes)
- 8+2 min
- FC-02.** How big is your hand and should you use it to skin score?
J. Scarisbrick (Birmingham), S. Morris (London) - 8+2 min
- FC-03.** Juvenile mycosis fungoides – cutaneous T-cell lymphoma with frequent follicular involvement.
I. Amitay-Laish, D. Ben-Amitai, M. Feinmesser, et al. (Petach Tikva) - 8+2 min
- FC-04.** MiR-223 has reduced expression and slows cell growth in mycosis fungoides/ cutaneous T-cell lymphoma.
L.Y. McGirt, J.A. Zic, C.M. Eischen (Nashville) - 8+2 min
- FC-05.** Mir-155 is involved in tumor progression of mycosis fungoides.
E. Hodak, A. Barzilai, B. Gorovitz, et al. (Petach Tikva)
- 8+2 min
- FC-06.** The role of versican isoforms in skin homing of Sézary cells.
M.B. Karpova (Zurich), K. Fujii (Okoyama), O. Georgiev (Zurich), et al. - presented by M. Urosevic-Maiwald - 8+2 min

19.00 **Welcome reception at the congress venue Parkhotel Schönbrunn.**
(cocktails and snacks)



Saturday, September 8, 2012

08.30-09.45 **S03: Targets for therapy I -
"Cellular & molecular targets"**

Chairs: W. Kempf and E. Berti

-
- S03-01.** Gene therapy for cutaneous lymphomas – light at the end of the tunnel?
M. Urosevic-Maiwald (Zurich) - 18 min
- S03-02.** Targeting IL21 in Sézary syndrome.
L. Van der Fits, J.J. Out-Luiting, S. Commandeur, et al. (Leiden)
- S03-03.** Pharmacological induction of p53 as a therapeutic approach in mycosis fungoides.
C. Savorani, V. Manfredi, E. Biskup, R. Gniadecki (Copenhagen) - 18 min
- S03-04.** Pre-clinical correlates of romidepsin sensitivity.
T. Trowe (San Francisco) - 18 min

09.45-10.00 **Coffee break**

10.00-12.15 **S04: Targets for therapy II –"clinical targets"**

Chairs: R. Willemze and C.D. Klemke

-
- S04-01.** Targeted therapies: past, present and future.
Y. Kim (Stanford) - 20 min
- S04-02.** Current status of combination therapies in mycosis fungoides/ Sézary syndrome.
M. Beyer, D. Humme, W. Sterry (Berlin) - 15 min
- S04-03.** Folliculotropic mycosis fungoides: from histopathology to the clinic. Is there a need for a new T-score?
P. Quaglino, M. Novelli, R. Ponti, et al. (Turin) - 15 min
- S04-04.** Mechanisms of resistance of mycosis fungoides to liposomal doxorubicine (Caelyx®). A study linked to clinical trial EORTC 2012.
N. Martínez, V. Monsálvez, M. Sánchez-Beato, et al. (Madrid) - presented by P.L. Ortiz Romero - 15 min

- S04-05.** Rituximab in combination with pegylated liposomal doxorubicin in diffuse large B-cell lymphoma, leg type: results of a pilot study .
C. Delfino (Florence), A. Fabbri (Siena), V. Grandi (Florence), et al. - 15 min
- S04-06.** Mycosis fungoides: risk of second lymphomas or other primary malignancies.
P. Savoia (Turin) - 15 min
- S04-07.** Allogeneic stem cell transplantation after reduced-intensity conditioning in advanced stage mycosis fungoides and Sézary syndrome.
F. Onida, G. Saporiti, E. Tagliaferri, et al. (Milan) - 15 min
- S04-08.** Non-myceloablative allogeneic transplant with total skin electron beam therapy, total lymphoid irradiation, and anti-thymocyte globulin demonstrates graft-versus-lymphoma effect while absent nonrelapse mortality in mycosis fungoides and Sézary syndrome.
W.K. Weng, M. Krathen, R. Armstrong et al. (Stanford) - presented by Y. Kim - 15 min

12.15-12.30 **Coffee break**

12.30-13.00 **Neil Smith memorial lecture**

Chair: R. Stadler

Cutaneous lymphomas: between Scylla and Charybdis.
L. Cerroni (Graz)

13.00-14.00 **Lunch**

14.00-15.30 **General assembly and clinical EORTC-trials**

15.30-15.45 **Coffee break**

15.45-18.15 **S05: Established therapies revisited**


Chairs: M. Bagot and C. Assaf

S05-01. Cutaneous gamma-delta T-cells under physiologic and pathologic conditions.

G. Stingl (Vienna) - 20 min

S05-02. Photopheresis in cutaneous T-cell lymphomas – update.

R. Knobler (Vienna) - 15 min



- S05-03.** Treatment of advanced cutaneous T-cell lymphomas with non-pegylated liposomal doxorubicin – consensus of the lymphoma group of the Dermatologic Cooperative Oncology Group.
R. Stadler (Minden) - 15 min
- S05-04.** Non-mycosis fungoides guidelines
E. Olsen (Durham) - 15 min
- S05-05.** Tarado trial update.
R. Dummer (Zurich) - 15 min
- S05-06.** Bexaroten side effect management.
M. Weichenthal (Kiel) - 15 min
- S05-07.** Brentuximab vedotin demonstrates clinical activity in mycosis fungoides and Sézary syndrome.
M. Krathen, S. Bashey, K. Wolpin, et al. (Stanford) - 15 min
- FC-07.** PUVA bath for follicular variant or early stage mycosis fungoides refractory to narrow band UVB.
F. Pavlotsky (Tel Hashomer), E. Hodak (Petach Tikva), D. Ben Amitay (Petach Tikva), et al. - 10 min
- FC-08.** UK consensus statement for bexarotene therapy in cutaneous T-cell lymphoma.
J. Scarisbrick, S. Morris, R. Azurdia et, al. (UK Cutaneous Lymphoma Group) - 10 min
- FC-09.** An NCR Phase II study of gemcitabine and bexarotene in the treatment of cutaneous T-cell lymphoma.
R. Cowan, S. Morris, J. Scarisbrick, et al. (UK Cutaneous Lymphoma Group) - 10 min
-

19.30 Shuttle bus departure from Parkhotel Schönbrunn

20.00 **Dinner at the Vienna City Hall**
Lichtenfelsgasse 2, 1010 Vienna



8.30-10.30 **S06: A look beyond**

Chairs: L. Papadavid and N. Pimpinelli

- S06-01.** Novel non-myeloablative hematopoietic stem cell transplantation in mycosis fungoides/Sézary syndrome
Y. Kim (Stanford) - 20 min
- S06-02.** A tribute to Warren L. Macaulay and CD30-LPD: Beyond the guidelines - critical and unsolved issues.
W. Kempf (Zurich) - 5+20 min
- S06-03.** Open questions in phototherapy.
P. Wolf (Graz) - 20 min
- S06-04.** Photodynamic therapy for folliculotropic mycosis fungoides: An open trial.
R. Gniadecki (Copenhagen) - 20 min
- FC-10.** NRAS mutations in cutaneous T-cell lymphoma sensitize tumors towards treatment with raf inhibitor sorafenib.
J.P. Nicolay (Heidelberg, Mannheim), M.K. Kiebling (Heidelberg), C.D. Klemke (Mannheim), et al. - 8+2 min
- FC-11.** Peripheral neuropathy in mycosis fungoides/Sézary syndrome treated with brentuximab vedotin.
S. Bashey, M. Krathen, K. Sutherland, et al. (Stanford) - 8+2 min
- FC-12.** Synergistic mechanism of histone deacetylase inhibitor and DNA methyltransferase inhibitor in cutaneous T-cell lymphoma treatment.
S. Rozati, P. Cheng, A. Fettelschoss (Zurich) - 8+2 min

10.30-11.00 **Coffee break**

11.00-12.40 **Free communications II**

Chairs: R. Knobler and F. Trautinger

- FC-13.** Diagnostic micro RNA profiling in cutaneous T-cell lymphoma.
T. Marstrand (Ballerup), U. Ralfkiaer (Copenhagen), C. Glue (Copenhagen), et al. - 8+2 min
- FC-14.** Expression and pathophysiological functions of T-plastin in cutaneous T-cell lymphoma.
E. Bégué, F. Jean-Louis, M. Bagot, et al. (Paris) - 8+2 min
- FC-15.** Immunocytochemical p63 expression in primary cutaneous B-cell lymphoma, further evidence for pathogenetic heterogeneity.
Z. Shukur, P. Coates, J. Goodlad, et al. (London) - 8+2 min

- FC-16.** Evaluation of follicular T-helper cells in primary cutaneous CD4+ small/medium sized pleomorphic T-cell lymphomas and a series of inflammatory dermatoses.
R.Y.P. Hunasehally, M. Ally, M. Rodriguez, et al. (London) - 8+2 min
- FC-17.** Expression of CD158k/kir3dl2 by skin-infiltrating CD30+ lymphocytes in patients with cutaneous anaplastic large T-cell lymphomas. A flow cytometric analysis.
M. Battistella, L. Michel, F. Jean-Louis, et al. (Paris) - 8+2 min
- FC-18.** Vascular endothelial growth factor (VEGF) expression in mycosis fungoides.
A. Pileri, C. Agostinelli, S. Righi, et al. (Bologna) - 8+2 min
- FC-19.** Human endogenous retrovirus type W envelope expression in mycosis fungoides provides new insights into cutaneous T-cell lymphomas.
P. Maliniemi (Helsinki), M. Vincendeau (Munich), J. Mayer (Saarbrücken), et al. - 8+2 min
- FC-20.** Notch1 signaling pathway activation study in cutaneous T-cell lymphomas.
F. Gallardo, R. Salgado, R. Garcia, et al. (Barcelona) - 8+2 min
- FC-21.** Combination of PLS3, TWIST, CD158K/KIR3DL2, and NKP46 gene expression for the diagnosis of Sézary syndrome.
L. Michel, F. Jean-Louis, E. Begue, et al. (Paris) - 8+2 min
- FC-22.** Secondary cancer and survival in mycosis fungoides or parapsoriasis: A Danish nationwide population based cohort study.
L.M. Lindahl, M. Fenger-Grøn, L. Iversen (Aarhus) - 8+2 min



Poster Session:

Posters will be on display during the entire congress.
The poster session is sponsored by:



-
- P01** Leukemia cutis in acute lymphatic leukemia.
E. Geissler, F. Meiss, A. Schmitt-Graeff, et al. (Freiburg)
- P02** Leukemia cutis as an initial manifestation of chronic myelomonocytic leukemia.
C. Duma, O. Inhoff, M. Hoffmann, et al. (Ludwigshafen)
- P03** Mucosal head and neck stage IVB mycosis fungoides.
Ch. Mikropoulos, M. Tsui, M. Wain, et al. (London)
- P04** Two cases of aggressive non-tumoral folliculotropic mycosis fungoides with pulmonary localization.
Brugière, Stefan, Domp martin, et al. (Caen)
- P05** Photopheresis plus PUVA for advanced mycosis fungoides. A demonstrative case.
H-M. Buenaventura, P-S. Yeray, M. Társila et al. (Las Palmas de Gran Canaria, Santa Cruz de Tenerife)
- P06** Mycosis fungoides with central nervous system involvement: A review of six cases from a single institution and a review of the role of low dose whole brain irradiation as an effective palliative treatment.
A. Mirza, St. Morris, B. Wilkins, et al. (London)
- P07** Analysis of lymphangiogenic markers in erythrodermic cutaneous T-cell lymphomas.
M.B. Karpova, K. Fujii, D. Jenni, et al. (Zurich, Okayama)
- P08** Erythrodermic vs tumour-stage mycosis fungoides: clinical onset extracutaneous progression and survival. A multicenter retrospective study from the Italian group of cutaneous lymphomas.
P.Quaglino, N. Pimpinelli, E. Berti, et al. (Turin, Florence, Milan, Brescia, Rome, Bologna)
- P09** Cutaneous tumour cell load correlates with survival in patients with Sézary syndrome.
N. Booken, J.P. Nicolay, C.-D. Klemke (Mannheim)
- P10** Genomic alterations study in Sézary syndrome.
L. Corti, D. Fanoni, L. Venegoni, et al. (Milan)
- P11** Retrospective review of extracorporeal photopheresis as monotherapy compared with extracorporeal photopheresis combined with other systemic biologic therapies in patients with Sézary syndrome.
S. Aguilar-Duran, SL. Morris, S. Whittaker, et al. (London)
- P12** Folliculotropic mycosis fungoides.
U. Badstöber, M.Schmid (Vienna)
- P13** Clonal heterogeneity in folliculotropic mycosis fungoides.
P. Mantaka, G. Trøen, P. Helsing, et al. (Oslo)

- P14** Folliculotropic mycosis fungoides: analysis of pilotropic T-cells.
O. Kontár, J. Csomor, N. Erős, et al. (Budapest)
- P15** Second neoplasm associated with primary cutaneous lymphomas.
M. Rodríguez-Vázquez, M. Luisa Martínez-Martínez, M. García-Arpa, et al. (Albacete)
- P16** The prevalence of primary cutaneous lymphomas at a dermatology referral center in Lower Austria.
J. Eder, A. Kern, M. Kitzwögerer, et al. (St.Pölten)
- P17** Cutaneous follicular helper T-cell lymphomas: a series of 6 cases highlighting new clinical-pathological aspects.
N. Ortonne, F. Kebir, D. Chatelain et al. (Créteil, Amiens, Paris, Carpentras, Caen)
- P18** Extranodal nasal-type natural killer/T-cell lymphoma mimicking refractory sinusitis in a 60-year-old-man.
H. Müller, B. Zelger, W. Willenbacher, et al. (Innsbruck, Graz)
- P19** Lymphomatoid papulosis associating massive eosinophilia and FIP1L1-PDGFRa fusion gene.
L. Curto, D. Sitjas, E. Llistosella, et al. (Barcelona)
- P20** Precursor blastic plasmacytoid dendritic cell neoplasia.
E. Berti, D. Fanoni, F. Novara, et al. (Milan, Pavia)
- P21** Indolent CD8+ lymphoid proliferation of acral sites: 7 cases including some atypical features.
D. Greenblatt, M. Ally, Z Shukur, et al. (London)
- P22** Two cases of blastic plasmacytoid dendritic cell neoplasm with exclusive skin localization treated with radiotherapy.
R. Piccinno, M. Caccialanza, E. Berti, et al. (Milan)
- P23** Primary cutaneous lymphomas at University Department of Dermatology and Venereology, Zagreb University Hospital Center, 2000-2010.
R. Ceovic, A. Pasic, J. Lipozencic, et al. (Zagreb)
- P24** t(8;9)(p22;p24)/PCM1-JAK2 Activates SOCS2/SOCS3 via STAT5 in cutaneous lymphoma cells.
S. Ehrentraut, S. Nagel, M.E. Scherr, et al. (Braunschweig)
- P25** withdrawn
- P26** BIOMED 2 multiplex T-cell receptor polymerase chain reaction protocol combined with heteroduplex analysis on Agilent bio-analyzer: interest in diagnosis of cutaneous T cell lymphoma.
C. Auzet, N. Bonnet, J.P. Dales, et al. (Marseille)
- P27** HSP 70 kDa protein 1A inhibits histone deacetylase inhibitor-induced apoptosis.
K. Fujii, N. Suzuki, T. Kaji, et al. (Okayama, Sapporo, Tokyo)
- P28** Ellipticine induced apoptosis in cutaneous T-cell lymphoma-importance of p53.
C. Savorani, V. Manfé, E. Biskup, et al. (Copenhagen)

- P29** Differential proteomic analysis in primary cutaneous marginal zone lymphoma.
V. Paulitschke, J. Eder, C. Jonak, et al. (St.Pölten, Vienna)
- P30** Recombinant anti-CD3-diphtheria toxin fusion protein in patients with cutaneous T-cell lymphoma.
Ch. Klade, J. Hodisch, O. Zahriychuk (Vienna)
- P31** Proteasome inhibition as a novel mechanism of the proapoptotic activity of gamma-secretase blocker I in cutaneous T-cell lymphoma.
M.R. Kamstrup, E. Biskup, V. Manfè, et al. (Copenhagen)
- P32** Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma with Burkitt translocation and CD158K/KIR3DL2 expression.
C. Ram-Wolff, Y. Reguerre, P. Brice, et al. (Paris, Angers)
- P33** Rituximab/Bendamustine combination therapy is an effective alternative in the treatment of primary cutaneous large B-cell lymphoma, leg-type, in elderly patients.
B. Arbacher-Stöger, R. Stadler (Minden)
- P34** Therapeutic attitude and evolution of a patient with T-cell-rich B-cell lymphoma.
C. Solovan, F. Baderca, S. Mohor (Timisoara)
- P35** Management of hyperlipidemia in cutaneous lymphoma patients treated with bexarotene.
U. Wehkamp, J. Becker, E. Geißler, et al. (Kiel, Würzburg, Freiburg, Erfurt, Ludwigshafen, Münster, Mannheim, Dresden, Tübingen, Zurich)
- P36** Ten years experience of bexarotene use and the regulation of plasma triglyceride levels by retinoid X receptor.
L.Väkevä, M. Robciuc, M. Jauhiainen, et al. (Helsinki)
- P37** Multifforme-like skin eruptions under bexarotene therapy in a patient with Sézary syndrome.
Christina Mitteldorf, Michael Tronnier (Hildesheim)
- P38** Positive impact of extracorporeal photopheresis on quality of life in patients with chronic graft-versus-host disease.
F.L. Dignan, S. Aguilar, J.J. Scarisbrick, et al. (London, Birmingham)
- P39** HIF-1 α - mediated regulation of Th17/Treg balance in the skin of cutaneous T-cell lymphoma patients.
M. Alcántara-Hernández, F. Jurado-Santacruz, G. Pérez-Montesinos, et al. (Mexico)
- P40** Preceding, concurrent or sequential occurrence of various neoplastic lymphoproliferative disorders (NLPD) in patients.
V. Nikolaou, A. Economidi, E. Papadavid, et al. (Athens)
- P41** Mycosis fungoides cases mimicking various inflammatory dermatoses.
A. Economidi, V.Nikolaou, E.Papadavid, et al. (Athens)

MAIN SPONSOR:



EXHIBITORS:




SPONSORS:



TARGRETIN[®]

das selektive Retinoid bei kutanem T-Zell-Lymphom



Targretin[®] 75 mg Weichkapseln. Wirkstoff: Bexaroten. **Zusatzstoffe:** Jede Kapsel enthält 75 mg Bexaroten. **Sonst. Bestandt.:** Kapselhülle: Macrogol, Polysorbat 20, Povidon, Butylhydroxyanisol (Ph.Eur.); Kapselhülle: Gelatine, Sorbitol-Spezialglycerolmischung (Glycerol, Sorbitol, Sorbitolanhydrid (1,4-Sorbitan), Mannitol (Ph.Eur.), Wasser), Titandioxid (E 171), Druckertinte (SDA 35A Alkohol (Ethanol und Ethylacetat), Propylenglycol (E 1520), Eisen(II,III)-oxid (E 172), Polyvinylacetatphthalat, gereinigtes Wasser, Isopropylalkohol, Macrogol 400, Ammoniumhydroxid 28 %). **Anw.gebiete:** Zur Behandl. v. Hautmanifestationen b. Pat. mit CTCL im fortgeschr. Stadium, d. auf mind. eine system. Behandl. nicht angesprochen haben. **Gegenanzeigen:** Überempfindlichkeit gegen Bexaroten od. e. d. sonst. Bestandt., Schwangerschaft u. Stillzeit, Frauen im gebärfähigen Alter ohne effektive Empfängnisverhütung, Vorgeschichte e. Pankreatitis, unkontrollierte Hypercholesterinämie/Hypertriglyceridämie, Hypervitaminose A, unkontrollierte Schilddrüsenerkrank., Leberinsuff., bestehende system. Infekt. **Nebenw.:** Sehr häufig: Leukopenie, Hypothyreose, Hyperlipämie, Hypercholesterinämie, exfoliative Dermatitis, Pruritus, Hautausschlag, Schmerzen, Kopfschmerzen, Asthenie; Häufig: lymphomähn. Reakt., Lymphadenopathie, hypochrome Anämie 1,2,3, Stör. d. Schilddrüsenfkt., Gewichtszunahme, erhöh. GÖT, erhöh. GPT, erhöh. LDH, erhöh. Kreatinin, Hypoproteinämie, Schwindelgefühl, Hypästhesie, Schlaflosigkeit, trockene Augen, Augenster., Taubheit, periph. Ödem, Erbrechen, Diarrhoe 1,3, Übelkeit 3, Anorexie 1, abnormale Leberfkt.s.tests, Cheilitis 2,3, trockener Mund 2,3, Verstopfung, Blähungen, Hautulzera, Alopezie 1, Hypertropie d. Haut, Hautknötchen, Akne, Schwitzen, trockene Haut 2,3, Hautstör., Knochenschmerzen, Arthralgie, Myalgie, allerg. Reakt., Infekt., Schüttelfrost 1, Bauchschmerzen, veränd. Hormonspiegel 1; Gelegentlich: Blutzykaskrasie, Purpura, Koagulationsstör., erhöh. Koagulationszeit 2,3, Anämie 1, Thrombozytopenie 3, Thrombozythämie, Eosinophilie 1, Leukozytose 2, Lymphozytose, Hypertthyreose, Gicht, Bilirubinämie 1,3, erhöh. Blutharnstoffwerte, herabgesetztes HDL, Ataxie, Neuropathie, Gleichgewichtsstör., Hyperästhesie, Depression 1,2,3, Erregung, spez. Linsentrübung 1,2,3, Amblyopie 3, Gesichtsfeldausfall, Hornhautverletzung, abnorm. Sehvermögen 1,2,3, Blepharitis, Bindehautentzünd. 3, Ohrenstör., Tachykardie, Hämorrhagien, Bluthochdruck, Ödem 3, Vasodilatation 1,2,3, Krampfadern, Pankreatitis 1,3, Leberversagen, gastrointest. Stör. 1, seröse Wundabsonderungen 1, Herpes simplex, pustulöser Ausschlag, Hautverfärbung 3, Haar- 1, Nagelstör. 1,3, Myasthenie 1, Albuminurie 1,3, abnorm. Nierenfkt., Neoplasma, Fieber 1,2,3, Cellulitis, Parasiteninfekt., Stör. d. Schleimhäute 3, Rückenschmerzen 1,2,3, abnorm. Laboregebnisse [1NW mit erhöh. Häufigkeit festgestellt, wenn Bexaroten-Dos. > 300 mg/m²/Tag, 2NW mit erhöh. Häufigkeit festgestellt, wenn Bexaroten-Dos. > 300 mg/m²/Tag od. b. Tumorpat. ohne CTCL; 3NW mit erhöh. Häufigkeit festgestellt, wenn Bexaroten-Dos. > 300 mg/m²/Tag (im Vergl. zur Verabreichung e. Dos. v. 300 mg/m²/Tag an Pat. mit CTCL) an Tumorpat. ohne CTCL]; NW b. Anfangsdos. > 300 mg/m²/Tag od. b. Tumorind. ohne CTCL: Neu beobacht.: Ekchymose, Petechien, abnorm. Leukozyten, herabgesetztes Thromboplastin, abnorm. Erythrozyten, Dehydratation, erhöh. gonadotropes LH, Gewichtsverlust, erhöh. alkal. Phosphatase, erhöh. Kreatininkinase, erhöh. Lipase, Hyperkalzämie, Migräne, periph. Neuritis, Parästhesie, Hypertonie, Verwirrung, Angstzustände, emotion. Labilität, Schläfrigkeit, herabgesetzte Libido, Nervosität, Nachtblindheit, Nyctagmus, Tränenflussstör., Tinnitus, Geschmacksinnstör., Brustschmerzen, Arrhythmie, periph. Gefäßstör., allg. Ödem, Hämoptyse, Dyspnoe, verstärkter Hustenreiz, Sinusitis, Pharyngitis, Dysphagie, Mundulzerierungen, orale Moniliasis, Stomatitis, Dyspepsie, Durst, abnorm. Stuhl, Aufstoßen, Ausschlag (vesikulöser, makulopapulärer), Beinkrämpfe, Hämaturie, Grippeyndr., Beckenschmerzen, Körpergeruch; Vereinzelt: Knochenmarkdepressionen, herabgesetztes Prothrombin, herabgesetztes gonadotropes LH, erhöh. Amylase, Hyponatriämie, Hypokalzämie, Hyperurikämie, Hypocholesterinämie, Hypolipämie, Hypomagnesiämie, abnorm. Gang, Stupor, zirkumorale Parästhesie, abnorm. Denken, Augenschmerzen, Hypovolämie, Subduralthämatom, kongestive Herzinsuff., Palpitation, Epistaxis, Gefäßanomalien u.-stör., Blässe, Pneumonie, Erkrank. d. Atemwege, Lungen- u. Brustfellerkrank., Cholezystitis, Leberschäden. (Cholestase-) Ikterus, Teerstuhl, Erbrechen, Laryngismus, Tenesmus, Rhinitis, erhöh. Appetit, Gingivitis, Herpes zoster, Psoriasis, Furunkulose, Kontaktdermatitis, Seborrhoe, flechtenähn. Dermatitis, Arthritis, Gelenkerkrank., Urinretention, gestör. Harnlassen, Polyurie, Nykturie, Impotenz, Urinabnormalitäten, Brustvergrößerung, Karzinom, photosensible Reakt., Gesicht-schwell, Unwohlsein, Virusinfekt., geschwollene Abdomen. Verkehrshinweis! **Verschreibungspflichtig. Zulassungsinhaber:** Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Vereinigtes Königreich. **Örtlicher Vertreter:** Teva GmbH, Graf-Arco-Str. 3, 89079 Ulm. Stand: April 2009.